Chronix’s ASCO presentation abstract disclosure
Chronix Biomedical, Inc., a developer of novel blood-based cancer molecular diagnostics, notes the formal disclosure of the abstract covering its forthcoming presentation of its study in head and neck cancer at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting on 5 June. Read more >>